



Madiha Iqbal, MBBS, MD¹, Han W. Tun, MD¹, Erel Joffe, MD, MSc², Christian Grommes, MD², Grzegorz Nowakowski, MD³, Matthew Lunning, DO⁴, Radhakrishnan Ramchandren, MD⁵, Chia-Cheng Li, DDS, DMSc⁶, Wanying Zhao, PhD⁶, Elizabeth Martinez, PhD⁶, Reinhard von Roemeling, MD⁶, Robert Earhart, MD, PhD⁶, Meaghan McMahon⁶, Iris Isufi, MD⁷, Lori Leslie, MD⁸, and Allison Rosenthal, DO⁹

¹Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic-Florida, Jacksonville, FL; ²Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY; ³Division of Hematology, Department of Internal Medicine, Mayo Clinic-Minnesota, Rochester, MN; ⁴University of Nebraska, Omaha, NE; ⁵University of Tennessee Medical Center, Knoxville, TN; ⁶Curis Inc., Lexington, MA; ⁷Yale New Haven Hospital, New Haven, CT; ⁸John Theurer Cancer Center, Hackensack, NJ; ⁹Department of Hematology, Mayo Clinic-Arizona, Phoenix, AZ

Background



BCR and TLR Pathways independently drive NF-κB overactivity (IMBRUVICA Package Insert, Rev 08/2018)





In preclinical testing, blocking both IRAK4 and BTK drove tumor reduction better than blocking either one alone (Booher et al. Waldenström Roadmap Symposium 2019)

IRAK4 is essential for TLR and IL-1R signaling in B-cell proliferation. It forms a Myddosome complex with MYD88 adaptor protein and drives overactivation of NF-κB, causing inflammation and tumor growth (1,2)

Emavusertib, a novel oral IRAK4 inhibitor, dosed twice daily has:

- Demonstrated an acceptable long term safety profile in monotherapy cohort of TakeAim Lymphoma trial
- Shown single agent activity in R/R NHL patients (3)
- Demonstrated the ability to overcome tumor resistance to ibrutinib and PI3K inhibitors in preclinical studies (4)
- Crossed the blood-brain barrier, reversed IRAK4 pathway activity and caused tumor regression, including cure in a murine PDX model with transplanted A20 NHL to the brain (5)
- Shown *in vivo* synergy in B-cell NHL in combination with ibrutinib (6)




B

Parameter	Units	Plasma	CSF (Naïve)	Brain (Naïve)	Brain (A20 Tumor)
C _{max}	µg/mL or µg/g	60.3 ± 19.26	1.42 ± 0.52	3.25 ± 1.41	3.22 ± 0.18
T _{max}	h	0.38 ± 0.14	0.25	0.5	0.83 ± 0.29
T _{1/2}	h	2.73	1.33	1.39	1.19
AUC _{0-8 h}	h*µg/mL or h*µg/g	189.51	2.91	8.09	8.68
AUC _{0-∞}	h*µg/mL or h*µg/g	224.46	2.96	8.72	9.39
Brain to plasma ratio	%		1.53	4.26	4.95

Brain penetration by emavusertib (A) Mean concentration of emavusertib in indicated samples over time. (B) Summary of pharmacokinetics data for emavusertib concentration in indicated samples established using UPLCS/MS. **Emavusertib showed single agent anti-tumor efficacy in PCNSL.** (C) Survival response in A20 PCNSL bearing mice treated with emavusertib. Treatment map included. P-values determined by Log-rank (Mantel-Cox) test, n=10 per group (5)

Study Design

TakeAim-Lymphoma (NCT03328078)
Part A2: dose escalation of emavusertib in combination with ibrutinib



- Endpoints include safety, tolerability, and RP2D
- As of October 12th, 2022, two patients with relapsed/refractory CNS lymphoma (CNSL) have been treated with emavusertib + ibrutinib combination therapy.

Baseline Characteristics

	Case 1	Case 2
Gender	Female	Male
Age (yrs)	66	65
Diagnosis	Primary CNSL	Secondary CNSL
MYD88 mutation	Yes (L265P)	NA
Prior BTK inhibitor / Best Response	Yes / PR	No / NA
# of measurable disease at baseline	2	1
Prior lines of anti-cancer therapy	2	4
Prior bone marrow transplant	No	Yes (autologous)

Safety Profile


Grade 3+ Treatment-Related Adverse Event	emavusertib (300 mg BID) + ibrutinib (560 mg QD)	
	Case 1	Case 2
Thrombocytopenia	Gr 3	-
Pain	Gr 3	-
Muscular weakness	Gr 3	-
Blood Bilirubin increased	-	Gr 3
Alanine aminotransferase increase	-	Gr 3
Aspartate aminotransferase increase	-	Gr 3

Data extracted October 12th, 2022

- No DLT and no treatment-related SAE was reported
- Majority of Gr 3 TRAEs were recovered or resolved

Results

- The preliminary efficacy data demonstrated one CR (**Case 1**) and one SD (**Case 2**).
- **Case 1** was originally intolerant to high-dose methotrexate-based chemoimmunotherapy and achieved PR after switching to ibrutinib. **Case 1** then achieved CR with emavusertib and ibrutinib combination therapy.
- **Case 2** achieved and maintained radiographic SD for ~5 months, with clinical resolution of associated symptoms.



Data extracted October 12th, 2022

Summary

- Preliminary data provide early clinical evidence of CNS penetration and anti-tumor activity of emavusertib.
- In R/R CNSL, the preliminary data suggest that combination therapy has a tolerable safety profile with promising anti-cancer activity and may overcome ibrutinib resistance.
- Trial enrollment is ongoing to further evaluate the clinical efficacy of emavusertib + ibrutinib combination therapy in CNSL.

References

1. Küppers et al. J Exp Med. 2015;212 (13):2184
2. Smith et al. Nat Cell Biol. 2019;21 (5):640-50
3. Nowakowski et al. Blood. 2020;36 (Suppl 1):44-45
4. Guidetti et al. AACR Mol Cancer Ther. 2021;20 (Suppl 12):P073
5. von Roemeling et al. AACR; Mol Cancer Ther. 2021;20 (Suppl 12):P243
6. Booher et al. Waldenström Roadmap Symposium. 2019

Acknowledgment

We would like to thank the patients, their families and caregivers for their invaluable contribution and participation in this study

Curis Contact: Reinhard von Roemeling, MD rvonroemeling@curis.com